Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab

NACompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2014

Conditions
Glaucoma
Interventions
DRUG

ranibizumab

Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.

PROCEDURE

standard care

standard post-operative care after trabeculectomy with mitomycin C

Trial Locations (1)

H1T2M4

Maisonneuve-Rosemont Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Maisonneuve-Rosemont Hospital

OTHER

NCT00892398 - Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab | Biotech Hunter | Biotech Hunter